Market Cap 269.64M
Revenue (ttm) 351.41M
Net Income (ttm) 880,000.00
EPS (ttm) N/A
PE Ratio 40.75
Forward PE 6.52
Profit Margin 0.25%
Debt to Equity Ratio -1.25
Volume 881,800
Avg Vol 1,246,388
Day's Range N/A - N/A
Shares Out 162.43M
Stochastic %K 83%
Beta 0.30
Analysts Sell
Price Target $0.92

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA na...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 621 7722
Fax: 617 494 0480
Address:
100 Summer Street, Suite 2300, Boston, United States
ASKING7
ASKING7 Oct. 27 at 8:45 PM
$IRWD $1.9 should be tested again this week, that will be a nice start for Nov
1 · Reply
Peterson28
Peterson28 Oct. 27 at 8:22 PM
$IRWD This is capped at 1.6-7 range to create the phantom premium so expect BO price to be around 3-3.5 plus CVR of 5-10. Still my base case.
0 · Reply
Nibbler
Nibbler Oct. 27 at 4:50 PM
0 · Reply
VSTN
VSTN Oct. 27 at 4:32 PM
$IRWD 🧐
0 · Reply
galaxySky
galaxySky Oct. 27 at 4:23 PM
$IRWD love when we break from $XBI
0 · Reply
revueltoL
revueltoL Oct. 27 at 1:30 AM
$IRWD maybe Tom somehow pulled off an incredible deal that even he and his yes-men can’t quite believe…perhaps we’re getting bought out at $2B….ok, I realize Tom isn’t exactly a business savvy guy but wild things have happened in this space…like Ironwood paying a stupid premium for VectivBio 😀
1 · Reply
Bio_Invest101
Bio_Invest101 Oct. 26 at 11:12 PM
$DAWN M&A Deal No. 10 in very hot Oct https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html $IRWD
0 · Reply
VSTN
VSTN Oct. 26 at 8:45 PM
$IRWD We have Goldman, we have Denner and we still have our dicks in our hand. Meanwhile…
1 · Reply
Solaf
Solaf Oct. 26 at 7:36 PM
$IRWD another big M&A: novartis to buy avidity for 12b. Get this company sold already.
1 · Reply
VSTN
VSTN Oct. 24 at 6:22 PM
$IRWD Still can’t believe this is trading at $260M market cap and 1/3 of the EV.
0 · Reply
Latest News on IRWD
Ironwood Pharmaceuticals Reports First Quarter 2025 Results

May 7, 2025, 7:05 AM EDT - 6 months ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results


Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results


Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results


Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20, 2024, 1:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC


ASKING7
ASKING7 Oct. 27 at 8:45 PM
$IRWD $1.9 should be tested again this week, that will be a nice start for Nov
1 · Reply
Peterson28
Peterson28 Oct. 27 at 8:22 PM
$IRWD This is capped at 1.6-7 range to create the phantom premium so expect BO price to be around 3-3.5 plus CVR of 5-10. Still my base case.
0 · Reply
Nibbler
Nibbler Oct. 27 at 4:50 PM
0 · Reply
VSTN
VSTN Oct. 27 at 4:32 PM
$IRWD 🧐
0 · Reply
galaxySky
galaxySky Oct. 27 at 4:23 PM
$IRWD love when we break from $XBI
0 · Reply
revueltoL
revueltoL Oct. 27 at 1:30 AM
$IRWD maybe Tom somehow pulled off an incredible deal that even he and his yes-men can’t quite believe…perhaps we’re getting bought out at $2B….ok, I realize Tom isn’t exactly a business savvy guy but wild things have happened in this space…like Ironwood paying a stupid premium for VectivBio 😀
1 · Reply
Bio_Invest101
Bio_Invest101 Oct. 26 at 11:12 PM
$DAWN M&A Deal No. 10 in very hot Oct https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html $IRWD
0 · Reply
VSTN
VSTN Oct. 26 at 8:45 PM
$IRWD We have Goldman, we have Denner and we still have our dicks in our hand. Meanwhile…
1 · Reply
Solaf
Solaf Oct. 26 at 7:36 PM
$IRWD another big M&A: novartis to buy avidity for 12b. Get this company sold already.
1 · Reply
VSTN
VSTN Oct. 24 at 6:22 PM
$IRWD Still can’t believe this is trading at $260M market cap and 1/3 of the EV.
0 · Reply
revueltoL
revueltoL Oct. 24 at 5:20 PM
$IRWD as in some african english accents, we have a real uncut “dim-ond” here..sell it Tom!
0 · Reply
VSTN
VSTN Oct. 24 at 4:55 PM
$IRWD Would be nice if this mofo participated in today’s rally
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 24 at 4:34 PM
$DAWN $IRWD Another deal today No.9 What a red hot Oct M&A market https://www.fiercepharma.com/pharma/roches-chugai-strikes-200m-ma-deal-take-over-igan-asset-several-asian-countries
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 24 at 3:54 PM
$IRWD Deal No 8 in Oct alone https://www.prnewswire.com/news-releases/lilly-to-acquire-adverum-biotechnologies-302593482.html $DAWN
0 · Reply
TeeMan123
TeeMan123 Oct. 24 at 3:02 PM
$IRWD this company's silence continues to be maddening... makes me worry they are working on some b.s. engineered deal, but if this mgmt team is in charge of anything involved with the go forward company it will not be a positive outcome for shareholders on announcement ... everyday there are examples of crap companies that are reporting weak news and seeing the stock explode higher (most recently VYTX and INBX) .. now is the time to strike a deal before the mood in the sector pivots to "sell the news"
1 · Reply
flyinghollaender
flyinghollaender Oct. 23 at 3:23 PM
$IRWD https://www.linkedin.com/posts/ironwood-pharmaceuticals_acg2025-shortbowelsyndrome-activity-7387110773669609473-DnT6?utm_source=share&utm_medium=member_ios&rcm=ACoAACuJPngBNwbiKUsqqtmN9OMBkk26OWeiQQ8
0 · Reply
Itinerant
Itinerant Oct. 23 at 12:27 PM
$IRWD This matter seems to me to be moving rather slowly. Perhaps my assessment is not correct. I have thought that they would like this matter finished up before year end. I expect that is still feasible. Opinions?
3 · Reply
Bio_Invest101
Bio_Invest101 Oct. 22 at 10:57 PM
$IRWD Takeda paid $1.2 B upfront cash plus $10 B biobucks for royalties and milestones to Innovent bio in anticipated revenues losses in 2030 after patent expires. They also own SBS drug Gattex fetched in $966 M revenues in 2024 and similar ranges for 2025. Gattex patent expires on 5/16/26 By the same logic Why not pay $1 B total cash to IRWD for both Linzess revenue 50% of $850 M and a quick and shorter confirmatory Ph3 Arpa that was paid for $1 B 2 yrs ago to fend off generic Gatter drug ? Takeda has the existing sales and market management team that can easily to jump start Apra upon FDA approval. I strongly believe there’re multiple suiters for Apra and of course that Linzess mature and stable REVENUE is super enticing to any BP or even to a small player in same field like ARDX. https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates
0 · Reply
revueltoL
revueltoL Oct. 22 at 9:35 PM
$IRWD thinking about it, a year is way too long to wait… need $10 a share in the next few weeks… Tom, make it happen!
1 · Reply
ASKING7
ASKING7 Oct. 22 at 8:11 PM
$IRWD whoever is doing this at close has been doing it for sometime and that group should already accumulate quite a lot
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 22 at 4:45 PM
$IRWD Deal No 7 in Oct. super hot https://www.businesswire.com/news/home/20251021765122/en/Hologic-to-be-Acquired-by-Blackstone-and-TPG-for-up-to-%2479-per-Share $DAWN
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 22 at 4:30 PM
$DAWN Our EU partner is busy doing deals This is No. 6 deal overall in Oct. lots of M&A happening in 4th Q https://www.fiercebiotech.com/biotech/ipsen-writes-check-worth-eu1b-acquire-next-gen-cancer-biotech $IRWD
0 · Reply